Next, to further demonstrate CD8+ T cells are the critical T-cell component that mediates the synergistic effect of the LB-100 and aPD-1 combination leading to durable tumor regression, CT26 tumor-bearing mice were subjected to CD8+ T-cell ablation using depleting antibodies prior to and during combination treatment (Fig. 1g). Here, CD8A is linked to neoplasm.